Unlocking Safe Adipocyte Energy Expenditure to Deliver Additional Weight Loss & Metabolic Benefits Beyond GLP-1s
1:30 pm - Thursday 10th December 2026
- Identifying first-in-class adipocyte targets at scale using an in vivo discovery platform designed to uncover mechanisms that drive weight loss beyond GLP-1 therapy
- Enhancing efficacy without compromising safety by targeting energy expenditure pathways in adipose tissue rather than traditional approaches associated with systemic safety concerns
- Delivering broader metabolic improvements including enhanced insulin sensitivity and lipid regulation, creating new opportunities for patients with obesity and type 2 diabetes who need more than weight loss alone
